
WHAT IS CLAIMED:

1. Use of a pharmaceutical formulation comprising a therapeutically effective amount of a ROCK2 inhibitor, in the manufacture of a medicament for the treatment of cerebral cavernous malformation (CCM), wherein the pharmaceutical formulation is to be orally administered to a patient in need thereof, and wherein

the ROCK2 inhibitor has the structure of Formula (A-I):



(A-I)

or a pharmaceutically acceptable salt thereof, wherein:

R^{A1} is selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, -OR^{A11}, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_x$-$C(=O)R^{A11}$, -O-(C_1-C_6 alkyl)$_{x1}$-$C(=O)R^{A11}$, -(C_1-C_6 alkyl)$_{x1}$-$C(=O)OR^{A11}$, -$C(=O)$-R^{A11}, -$C(=O)OR^{A11}$, -(C_1-C_6 alkyl)$_{x1}$-$C(=O)NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-$C(=O)R^{A11}$, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-$C(=O)OR^{A11}$;

R^{A2} is selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, -OR^{A11}, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-$C(=O)R^{A11}$, -O-(C_1-C_6 alkyl)$_{x1}$-$C(=O)R^{A11}$, -(C_1-C_6 alkyl)$_{x1}$-$C(=O)OR^{A11}$, -$C(=O)$-R^{A11}, -$C(=O)OR^{A11}$, -(C_1-C_6 alkyl)$_{x1}$-$C(=O)NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-$C(=O)R^{A11}$, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-$C(=O)OR^{A11}$;

alternatively, R^{A1} and R^{A2} are taken together to form a 5- or 6-membered saturated or unsaturated fused ring which may contain from 0 to 2 ring heteroatoms selected from the group consisting of N, O, and S, and which is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C_1-C_6 alkyl, halo, -CN, -OH, oxo, -O-(C_1-C_6 alkyl), -O-(C_1-C_6 alkyl)-OH, -O-(C_1-C_6 alkyl)-O-(C_1-C_6 alkyl), -

$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, C_1-C_3 perfluoro alkyl, -NR^{A11}-(C_1-C_6 alkyl)$NR^{A11}R^{A12}$, and -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11};

R^{A3} and R^{A4} are each independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, 3- to 10-membered heterocyclyl, C_6-C_{10} aryl, 5- to 14-membered heteroaryl, C_{6-12} aralkyl, -(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, and -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$;

alternatively R^{A3} and R^{A4} are taken together with the nitrogen to which they are attached to provide (i) a 4- to 6-membered heterocyclic ring having from 0 to 2 additional ring to heteroatoms selected from N, O and S, or (ii) a 5- to 10-membered hetero bicyclic ring system having from 0 to 3 additional ring heteroatoms selected from N, O and S; wherein the heterocyclic ring or the bicyclic ring system are unsubstituted or are substituted with from 1 to 4 substituents selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, -OR^{A11}, oxo, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -O-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, -C(=O)-R^{A11}, -C(=O)OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11};

the dotted lines represent optional double bonds;

each R^{A5} is independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, oxo, -OR^{A11}, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -O-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, -C(=O)-R^{A11}, -C(=O)OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11};

n1 is 0 to 3;


R^{A7} is independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, -(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, and -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$;

each *x1* is independently selected from 0 and 1; and

each R^{A11} and R^{A12} are independently selected from the group consisting of H and C_1-C_6 alkyl;

or alternatively, R^{A11} and R^{A12} are taken together when both are attached to the same nitrogen to form a 4- to 7- membered heterocyclic ring having from 0 to 2 additional ring heteroatoms selected from the group consisting of N, O and S, and which heterocyclic ring is unsubstituted or is substituted with 1 to 3 substituents selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, -CN, -NH_2, C_1-C_3 perfluoro alkyl, -OH, -O-(C_1-C_6 alkyl), and -(C_1-C_6 alkyl)-OH.


2. The use of claim 1, wherein the ROCK2 inhibitor has the formula:



or a pharmaceutically acceptable salt thereof.

3. Use of a pharmaceutical formulation comprising:


(a) about 1 to about 15 wt % of a compound having a structure:



or a pharmaceutically acceptable salt thereof;

(a) about 15 to 50 wt% of a fatty acid component comprising saturated and/or unsaturated C_8-C_{24} fatty acids and/or a pharmaceutically acceptable salt thereof;

(b) about 30 to 50 wt% of a first glyceride component comprising one or more glyceride compounds having a structure of Formula (I)



(I)


wherein:

each R^1, R^2, and R^3 is independently hydrogen or -C(O)-R^A;

each R^A is independently C_7-C_{21} alkenyl comprising one or two double bonds,

provided that at least one of R^1, R^2, and R^3 is not hydrogen; and

(c) about 10 to 35 wt% of a second glyceride component comprising one or more glyceride compounds having a structure of Formula (II)



(II)


wherein:

each R^4, R^5, and R^6 is independently hydrogen, or -C(O)-R^B;

each R^B is independently C_7-C_{21} alkyl,

provided that at least one of R^4, R^5, and R^6 is not hydrogen,

in the manufacture of a medicament for the treatment of cerebral cavernous malformation (CCM), wherein the pharmaceutical formulation is to be administered orally to a patient in need thereof.

4. The use of claim 3, wherein the active pharmaceutical agent (API) comprises an HCl salt of 

.




5. The use of claim 3 or claim 4, wherein the fatty acid component comprises a saturated or unsaturated C_{12}-C_{18} fatty acid and/or a pharmaceutically acceptable salt thereof.

6. The use of claim 3, wherein

a) the fatty acid component comprises an oleic acid, sodium oleate, or a combination thereof;

b) the first glyceride component comprises the one or more glyceride compounds having a structure of Formula (I) and each R^A is independently C_7-C_{21} alkenyl comprising one or two double bonds;




c) the first glyceride component comprises one or more glyceride compounds having the structures:

 (Ia),  (I-b), and  (I-c),

optionally wherein a ratio of the compound of Formula (I-a), the compound of Formula (I-b), and the compound of Formula (I-c) is about 32 to 52 : 40 to 55: 5 to 20;


d) the second glyceride component comprises one or more compounds having a structure of Formula (II) and each R^B is independently C_7-C_{21} alkyl;

e) the second glyceride component comprises the one or more glyceride compounds having one of the following structures:

 (II-a),  (II-b), and  (II-c);

f) the API is formulated in a solid dispersion, in a solution, or as combination thereof;

g) the pharmaceutical formulation comprises the compound having a structure

 or a pharmaceutically acceptable salt thereof in an amount of about 1-10 wt % of the pharmaceutical formulation, or from about 2-8 wt % of the pharmaceutical formulation, or from about 5-7 wt % of the pharmaceutical formulation;

h) the pharmaceutical formulation comprises the fatty acid component in an amount of about 20 to 45 wt%, about 30 to 45 wt%, about 35 to 45 wt%, or about 35 to 40 wt%, based on the weight of the pharmaceutical formulation;

i) the pharmaceutical formulation comprises:

a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acid in an amount of 12 to 48 wt%, about 15 to 45 wt%, about 25 to 40 wt%, about 30 to 40 wt%, or about 35 to 40 wt%; and

a sodium salt of a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acids in an amount of about 1 to 5 wt%, or about 2 to 4 wt%, or about 2 to 3 wt%,

based on the weight of the pharmaceutical formulation;

j) the pharmaceutical formulation comprises the first glyceride component in an amount of about 30 to 45 wt%, or about 32 to 40 wt%, or about 35 to 40 wt% based on the weight of the pharmaceutical formulation;

k) the pharmaceutical formulation comprises the second glyceride component in an amount of about 10 to 30 wt%, or about 10 to 20 wt%, or about 15 to 18 wt% based on the weight of the pharmaceutical formulation; or

l) the pharmaceutical formulation comprises:

Compound A, or a pharmaceutically acceptable salt in an amount of about 1-15 wt %;

a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acid in an amount 12 to 48 wt%;


a sodium salt of a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acids in an amount of about 1 to 5 wt%;

the first glyceride component in an amount of about 30 to 50 wt%; and

the second glyceride component in an amount of about 10 to 35 wt%,

based on the weight of the pharmaceutical formulation.

7. Use of a pharmaceutical formulation comprising a therapeutically effective amount of a ROCK2 inhibitor in the manufacture of a medicament for the treatment of Devic's disease, wherein the pharmaceutical formulation is to be orally administered to a patient in need thereof.
8. The use of claim 7, wherein the ROCK2 inhibitor has the structure of Formula (A-I):



(A-I)

or a pharmaceutically acceptable salt thereof,

wherein:

R^{A1} is selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, -OR^{A11}, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_x$-C(=O)R^{A11}, -O-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, -C(=O)-R^{A11}, -C(=O)OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11};

R^{A2} is selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, -OR^{A11}, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -O-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, -C(=O)-R^{A11}, -C(=O)OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11};

alternatively, R^{A1} and R^{A2} are taken together to form a 5- or 6-membered saturated or unsaturated fused ring which may contain from 0 to 2 ring heteroatoms selected from the group consisting of N, O, and S, and which is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C_1-C_6 alkyl, halo, -CN, -OH, oxo, -O-(C_1-C_6 alkyl), -O-(C_1-C_6 alkyl)-OH, -O-(C_1-C_6 alkyl)-O-(C_1-C_6 alkyl), -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, C_1-C_3 perfluoro alkyl, -NR^{A11}-(C_1-C_6 alkyl)$NR^{A11}R^{A12}$, and -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11};

R^{A3} and R^{A4} are each independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, 3- to 10-membered heterocyclyl, C_6-C_{10} aryl, 5- to 14-membered heteroaryl, C_{6-12} aralkyl, -(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6

alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, and -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$;

alternatively R^{A3} and R^{A4} are taken together with the nitrogen to which they are attached to provide (i) a 4- to 6-membered heterocyclic ring having from 0 to 2 additional ring to heteroatoms selected from N, O and S, or (ii) a 5- to 10-membered hetero bicyclic ring system having from 0 to 3 additional ring heteroatoms selected from N, O and S; wherein the heterocyclic ring or the bicyclic ring system are unsubstituted or are substituted with from 1 to 4 substituents selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, -OR^{A11}, oxo, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -O-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, -C(=O)-R^{A11}, -C(=O)OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11};

the dotted lines represent optional double bonds;

each R^{A5} is independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, halo, -CN, C_1-C_3 perfluoro alkyl, oxo, -OR^{A11}, -O-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-OR^{A11}, -$NR^{A11}R^{A12}$, -O-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -O-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, -C(=O)-R^{A11}, -C(=O)OR^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$, -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, and -NR^{A11}-(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11};

n1 is 0 to 3;

R^{A7} is independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, -(C_1-C_6 alkyl)-OR^{A11}, -(C_1-C_6 alkyl)-$NR^{A11}R^{A12}$, -(C_1-C_6 alkyl)$_{x1}$-C(=O)R^{A11}, -(C_1-C_6 alkyl)$_{x1}$-C(=O)OR^{A11}, and -(C_1-C_6 alkyl)$_{x1}$-C(=O)$NR^{A11}R^{A12}$;


each *x1* is independently selected from 0 and 1; and

each R^{A11} and R^{A12} are independently selected from the group consisting of H and C_1-C_6 alkyl;

or alternatively, R^{A11} and R^{A12} are taken together when both are attached to the same nitrogen to form a 4- to 7- membered heterocyclic ring having from 0 to 2 additional ring heteroatoms selected from the group consisting of N, O and S, and which

heterocyclic ring is unsubstituted or is substituted with 1 to 3 substituents selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl, -CN, -NH_2, C_1-C_3 perfluoro alkyl, -OH, -O-(C_1-C_6 alkyl), and -(C_1-C_6 alkyl)-OH.


9. The use of claim 8, wherein the ROCK2 inhibitor has the formula:



or a pharmaceutically acceptable salt thereof.

10. Use of a pharmaceutical formulation comprising:


(a) about 1 to about 15 wt % of a compound having a structure:



or a pharmaceutically acceptable salt thereof;

(b) about 15 to 50 wt% of a fatty acid component comprising saturated and/or unsaturated C_8-C_{24} fatty acids and/or a pharmaceutically acceptable salt thereof;

(c) about 30 to 50 wt% of a first glyceride component comprising one or more glyceride compounds having a structure of Formula (I)




(I)

wherein:

each R^1, R^2, and R^3 is independently hydrogen or -C(O)-R^A;

each R^A is independently C_7-C_{21} alkenyl comprising one or two double bonds, provided that at least one of R^1, R^2, and R^3 is not hydrogen; and

(d) about 10 to 35 wt% of a second glyceride component comprising one or more glyceride compounds having a structure of Formula (II)

 (II)


wherein:

each R^4, R^5, and R^6 is independently hydrogen, or -C(O)-R^B;

each R^B is independently C_7-C_{21} alkyl,

provided that at least one of R^4, R^5, and R^6 is not hydrogen,

in the manufacture of a medicament for the treatment of Devic's disease, wherein the pharmaceutical formulation is to be administered orally to a patient in need thereof.

11. The use of claim 10, wherein the active pharmaceutical ingredient (API) comprises an HCl salt of .




12. The use of claim 10 or claim 11, wherein the fatty acid component comprises a saturated or unsaturated C_{12}-C_{18} fatty acid and/or a pharmaceutically acceptable salt thereof.

13. The use of claim 10, wherein

a) the fatty acid component comprises an oleic acid, sodium oleate, or a combination thereof;

b) the first glyceride component comprises the one or more glyceride compounds having a structure of Formula (I) and each R^A is independently C_7-C_{21} alkenyl comprising one or two double bonds;




c) the first glyceride component comprises one or more glyceride compounds having the structures:

 (Ia),  (I-b), and  (I-c);

optionally wherein a ratio of the compound of Formula (I-a), the compound of Formula (I-b), and the compound of Formula (I-c) is about 32 to 52: 40 to 55: 5 to 20;


d) the second glyceride component comprises one or more compounds having a structure of Formula (II) and each R^B is independently C_7-C_{21} alkyl;

e) the second glyceride component comprises the one or more glyceride compounds having one of the following structures:


(II-a),

(II-b), and

(II-c);

f) the API is formulated in a solid dispersion, in a solution, or as combination thereof;

g) the pharmaceutical formulation comprises the compound having a structure of


or a pharmaceutically acceptable salt thereof in an amount of about 1-15 wt % of the pharmaceutical formulation, or from about 1-10 wt % of the pharmaceutical formulation, or from about 2-8 wt % of the pharmaceutical formulation, or from about 5-7 wt % of the pharmaceutical formulation;

h) the pharmaceutical formulation comprises the fatty acid component in an amount of about 20 to 45 wt%, about 30 to 45 wt%, about 35 to 45 wt%, or about 35 to 40 wt%, based on the weight of the pharmaceutical formulation;

i) the pharmaceutical formulation comprises:

a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acid in an amount of 12 to 48 wt%, about 15 to 45 wt%, of about 25 to 40 wt%, about 30 to 40 wt%, or about 35 to 40 wt%; and

a sodium salt of a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acids in an amount of about 1 to 5 wt%, or about 2 to 4 wt%, or about 2 to 3 wt%,

based on the weight of the pharmaceutical formulation;

j) the pharmaceutical formulation comprises the first glyceride component in an amount of about 30 to 45 wt%, or about 32 to 40 wt%, or about 35 to 40 wt% based on the weight of the pharmaceutical formulation;

k) the pharmaceutical formulation comprises the second glyceride component in an amount of about 10 to 30 wt%, or about 10 to 20 wt%, or about 15 to 18 wt% based on the weight of the pharmaceutical formulation; or

l) the pharmaceutical formulation comprises:

- Compound A, or a pharmaceutically acceptable salt in an amount of about 1-15 wt %;
- a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acid in an amount 12 to 48 wt%;
- a sodium salt of a fatty acid having saturated or unsaturated C_{12}-C_{18} fatty acids in an amount of about 1 to 5 wt%;
- the first glyceride component in an amount of about 30 to 50 wt%; and
- the second glyceride component in an amount of about 10 to 35 wt%,

based on the weight of the pharmaceutical formulation.